Collegium Pharmaceutical, Inc.
COLL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.05 | -1.22 | 1.01 |
| FCF Yield | 7.08% | 7.69% | 5.75% | 9.15% |
| EV / EBITDA | 15.37 | 17.56 | 21.09 | 17.71 |
| Quality | ||||
| ROIC | 3.78% | 2.07% | 1.39% | 2.27% |
| Gross Margin | 61.70% | 57.65% | 54.75% | 54.02% |
| Cash Conversion Ratio | 2.49 | 6.05 | 22.92 | 6.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.47% | 9.61% | 8.16% | 10.82% |
| Free Cash Flow Growth | 8.12% | 32.55% | -35.06% | 1,009.60% |
| Safety | ||||
| Net Debt / EBITDA | 6.30 | 7.56 | 9.29 | 8.18 |
| Interest Coverage | 2.92 | 1.72 | 1.04 | 1.68 |
| Efficiency | ||||
| Inventory Turnover | 2.11 | 2.09 | 2.16 | 2.35 |
| Cash Conversion Cycle | 134.69 | 132.79 | 137.47 | 147.07 |